Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.

Marschner, N., Müller, L., Münch, A., Blumenstengel, K., Hutzschenreuter, U., Busies, S., 2017.

J Oncol Pharm Pract 23(4), 288–295. doi:10.1177/1078155216632379

Studie: TNK; Indikation: Nierenzellkarzinom; Jahr: 2017; Veranstaltung: -; Journal: Journal Oncology Pharmacy Practice

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com